Evaluation of Injection Site Pain and Adherence in Patients Transitioning from a High to Low Volume Adalimumab Formulation (AVT02, Simlandi®) Across Multiple Indications (EASE PAIN)

Key Points

• Assess injection site pain and medication adherence when transitioning between high and low volume adalimumab formulations.
• Conducted a clinical trial with patients transitioning to AVT02 (Simlandi®) formulation.
• Evaluated pain levels at injection sites during therapy.
• Monitored medication adherence throughout the transition process.
• Identified changes in injection site pain metrics during the transition.
• Noted adherence rates following the switch to the low volume formulation.